Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 132 clinical trials
Featured trial
A Phase 2 Trial of Combination Therapies With Adagrasib in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (202200050434)

Study 849-017 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of combination therapies with adagrasib in patients with advanced NSCLC with TPS ≥ 1% and KRAS G12C

pembrolizumab
KRAS
  • 38 views
  • 20 Dec, 2022
  • 24 locations
Featured trial
Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-12)

This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 versus docetaxel in patients who have been previously treated for metastatic NSCLC with a KRAS G12C mutation

KRAS
metastatic non-small cell lung cancer
advanced lung cancer
recurrent non-small cell lung cancer
refractory non-small cell lung cancer
  • 37 views
  • 27 Dec, 2022
  • 202 locations
Featured trial
Metastatic Colorectal Cancer with wild-type KRAS tumors.

Metastatic Colorectal Cancer with wild-type KRAS tumors.

  • 270 views
  • 25 Mar, 2021
  • 1 location
Featured trial
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation

Evaluates the safety, tolerability, pharmacokinetics, metabolites, pharmacodynamics, and clinical activity of MRTX849 in patients with advanced solid tumors with a KRAS G12C mutation. MRTX849 is

solid tumor
malignant solid tumor
advanced solid tumor
  • 538 views
  • 22 Nov, 2021
  • 62 locations
Featured trial
A Phase 1/2 Trial of MRTX849 in Combination with TNO155 in Patients with Advanced Solid Tumors with KRAS G12C Mutation

Characterize the safety and tolerability, and evaluate Pharmacokinetics of MRTX849 in combination with TNO155 in patients with advanced solid tumor malignancies with KRAS G12C mutation.

solid tumor
malignant solid tumor
advanced solid tumor
solid tumors
  • 179 views
  • 19 Feb, 2021
  • 4 locations
Therascreen® KRAS RGQ PCR Kit

for the KRAS G12C mutation for potential inclusion into the Amgen Phase III clinical trial (Protocol No 20190172) to demonstrate clinical performance of the therascreen® KRAS RGQ PCR Kit

  • 0 views
  • 14 May, 2022
  • 1 location
A Study of GFH925 in Patients With Advanced Solid Tumors With KRAS G12C Mutations

Phase I: To evaluate the safety and tolerability of GFH925 in subjects with KRAS G12C mutant advanced solid tumors and estimate the maximum tolerated dose (MTD) and/or a recommended phase 2 dose

  • 0 views
  • 04 Oct, 2022
  • 1 location
Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas

This is a prospective one-arm, two-stage phase 2 trial of TVB-2640 in KRAS mutant NSCLC patients. 13 patients will be treated with a minimum of 1 cycle of TVB-2640 therapy over 8 weeks.

  • 1 views
  • 06 Mar, 2022
  • 1 location
Pilot Study of Mature Dendritic Cell Vaccination Against Mutated KRAS in Patients With Resectable Pancreatic Cancer

This research study is designed to evaluate the effects of a dendritic cell (kind of white blood cell) vaccine for pancreatic cancer.

cancer
KRAS
  • 3 views
  • 21 Oct, 2022
  • 1 location
A Trial of mFOLFIRI With MEK162 in Patients With Advanced RAS (HRAS, NRAS, or KRAS) Positive Metastatic Colorectal Cancers

This is a Phase 1b, open label, dose-finding study to determine the Maximum Tolerated Dose (MTD) of MEK162 in combination with mFOLFIRI, and to evaluate the response rate, clinical benefit rate and additional safety parameters of the treatment combination

  • 4 views
  • 06 May, 2022
  • 1 location